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LetterPrevalence of Donor-Specific Antibodies
After Pediatric Liver Transplantation:
A Meta-Analysis
Jesper M. Kivelä, MD1Our recent study showed that donor-specific HLA anti-bodies (DSAs)were common after pediatric liver trans-
plantation (LT).1 The aim was to conduct a meta-analysis of
DSA prevalence after pediatric LT.
PubMed was used (as of March 1, 2016) with a search
strategy:Human leucocyte antigen antibod*ORHLAantibod*
OR donor-specific antibod*OR donor specific antibod*OR
DSAsAND liver transplantationAND (pediatricOR children).
Studies published before January 1, 2000, were excluded
based on a rationale for HLA antibody detection technology
advancement.
References were screened, and data were extracted from
the eligible studies based on 3 criteria: (1) patients under-
went LT <18 years of age, (2) prevalence of DSAs was evalu-
ated after LT, and (3) patients were on some form of
immunosuppression at the time of DSAs. Studies with mixed
population of adults and children were included if informa-
tion was available for pediatric patients separately or if aver-
age age of patients were under 18 years at LT. Unit of analysis
was the proportion of patients with DSAs of total number of
patients analyzed for DSAs.
R version 3.1.1 (www.r-project.org) was used with meta
package2 to calculate overall prevalence with 95% confi-
dence interval (CI). The overall prevalence was calculated
with the use of logit transformation. A random-effects modelReceived 19 September 2016.
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average prevalence estimate across the studies is obtained un-
der the random-effects model. In addition, 95% prediction
interval (PI) was calculated to obtain a predicted range of true
DSA prevalence for a new analogous study. The details of PI
have been described elsewhere.3
Literature search yielded 28 references of which 8 were in-
cluded in the analysis. One study missed in the aforemen-
tioned search was included based on an earlier knowledge
of its existence (total of 9 studies). Reasons for exclusionwere
mixed population (n = 5), intestinal transplantation (n = 5),
case reports (n = 3), review (n = 2), editorial (n = 1), DSAs
evaluated only prior LT (n = 1), overlapping study popula-
tion (n = 1), patients not on immunosuppression (n = 1),
and full text not available (n = 1). Some of the studies had
multiple reasons for exclusion.
Age at the time of LT varied between studies (Table 1).
Two of the studies included patients not on immunosuppres-
sion at the time of DSAs (Table 1 footnote).
Total sample size was 322 patients (Figure 1). Average
prevalence of DSAswas 41% (95%CI, 29%-54%) although
prevalence varied across studies as evident with the heteroge-
neity statistics (I2 = 77% [95%CI, 56%-88%], P < 0.001 for
heterogeneity). The PI indicated that the true DSA prevalence
for a new analogous studywill fall 95%of times within inter-
val of 11% to 80%.
There was little influence on heterogeneity when omitting
1 study at the time. The largest impact on heterogeneity
was observed after excluding study by Waki et al4 (I2 from
77% to 66%) or study by Markiewicz-Kijewska et al5 (I2
from 77% to 71%). Average DSA prevalence was 51%
(95%CI, 43%-58%) after excluding these 2 studies simulta-
neously. Heterogeneity also diminished (I2 = 29% [95% CI,
0%-69%], P = 0.207), and the PI also became narrower as
expected (34% to 67%). The other excluded study evaluated
DSAs shortly after LT (at 3 weeks).4
This study has limitations. First, only 1 author extracted
the data which can bias the extraction process. Second, the
literature search was simple and based only on 1 database.
Third, the impact of different study characteristics on hetero-
geneity was not assessed.
These limitations in mind, the average DSA prevalence
was 41% (95%CI, 29%-54%) across 9 studies after pediat-
ric LT although variability between studies was noticeable.www.transplantationdirect.com 1
TABLE 1.
List of included studies
Study (year) Age at LT Follow-up timea LT type DSA positive of total (%) MFI level for positivity
Girnita (2010)b 4.1 y 8.2 y DDLT/LDLT 9/12 (75.0) N/A
Goh (2010)c N/A N/A DDLT 6/21 (28.6) 1000
Feng (2012) 6.9 mo 6.1/8.4 yd LDLT 9/18 (50.0) N/A
Miyagawa-Hayashino (2012) 1. y 11 y LDLT 32/67 (47.8)e 1000
Waki (2013) 2.2/4.3 yf 3 wk LDLT 3/36 (8.3) 1000
Markiewicz-Kijewska (2015) 0.97 y 6.8 y LDLT 5/33 (15.2) N/A
Wozniak (2015) 3.7 y 12.3/12.2 y DDLT/LDLT 27/50 (54.0)g 1000
Grabhorn (2015) 11.9/8.6 yh 10.0/4.8 y DDLT/LDLT 20/43 (46.5) 1500
Kivelä (2016) 2.6 y 11.2 yi DDLT 25/42 (59.5)j 1000
Girnita et al. Hum Immunol 2010; 71: 274-6. Goh et al. Liver Transpl 2010: 16: 308-13. Feng et al. JAMA 2012; 307: 283-93. Miyagawa-Hayashino et al. Liver Transpl 2012; 18: 1333-1342. Waki et al.
Transplantation 2013; 95: 177-183. Markiewicz-Kijewska et al. Ann Transplant 2015; 20: 279-284. Wozniak et al. Transplantation 2015; 99: 1416–1422. Grabhorn et al. Transplantation 2015; 99:
1876-1881. Kivelä et al. Transplant Int 2016; 29: 494-505. Study by Feng et al was missed with the search strategy used.
a Follow-up time refers to time from LT to blood sample drawn for DSA analyses if applicable.
b Part of the total sample (group B) is only included. Based on mean age 4.1 and (assumed) standard deviation 8.7 indicates that some of patients were outliers considering their age at the time of LT.
c DSAs were evaluated after first LT and before second LT. Descriptive statistics provided only for second LT. DDLT assumed as LT type based on second LTs.
d Time from LT to study entry (median 73.0 months for nontolerant and 100.6 months for tolerant patients).
e Patients not on immunosuppression were included (n = 4; all DSA negative patients).
f For OT patients mean 2.2 years and non-OT mean 4.3 years.
g Tolerant (ie, not on immunosuppression) patients included (n = 7; 2 DSA positive).
h For excellent graft function patients mean age 11.9 years and for chronic rejection patients 8.6 years. Maximum age at the time of LT was 26 years in excellent graft group.
i Median follow-up time for LT patients (n = 42) only.
j Combined liver-kidney transplantation patients (n = 8; 1 DSA positive) excluded.
DDLT, deceased donor liver transplantation; DSA, donor-specific antibody; LDLT, living donor liver transplantation; MFI, mean fluorescence intensity; OT, operational tolerant.
FIGURE 1. Average (95%CI) prevalence of 41% (29% to 54%) (grey diamond) for DSAs after pediatric LT. I2 is shown with 95% CI. I2 depicts
that 77% of variability in DSA prevalence estimates across studies is beyond sampling error (ie, due to heterogeneity). CIs for individual studies
were calculated with the method by Clopper-Pearson. Between-study variance (τ2) was estimated with the method by DerSimonian and Laird.
The prediction interval (black solid line) refers to a predicted interval of true DSA prevalence for a new analogous study.
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